Plain-English translation of NCT06334133 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Diabetes Mellitus, Type 1 research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This 26-week trial is testing cadisegliatin, a new medication designed to work alongside insulin to help prevent dangerous drops in blood sugar (hypoglycemia) in people with type 1 diabetes. About 150 participants will randomly receive either the medication at one of two doses or a placebo (inactive pill) alongside their regular insulin treatment. The study aims to measure whether this medication actually reduces how often people experience severe low blood sugar episodes.
Even with careful insulin management, people with type 1 diabetes can experience frightening and dangerous episodes of extremely low blood sugar. This medication is being studied to see if it can provide extra protection and help prevent these scary episodes from happening in the first place.
You would come in for screening and training visits over about 2 months, then continue your normal insulin routine while taking either the new medication or a placebo daily for 26 weeks. You'll continue using your continuous glucose monitor and insulin pump or injections as usual. The study team will track your blood sugar patterns and any low blood sugar episodes throughout the 26 weeks to see if the medication helps protect you.
AI-generated summary from trial data · Aug 8, 2026 · Not medical advice
United States